Condition: Overweight · Obesity · Sponsor: Novo Nordisk A/S
The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as oral tablets once a day. Participants will either get zenagamtide (the treatment being tested) or Placebo (treatment that has no active medicine in it). Which treatment participants get is decided by chance.
This description comes directly from the study's public registry record.
Novo Nordisk · (+1) 866-867-7178 · clinicaltrials@novonordisk.com
Always discuss trial participation with your own doctor first.
| Pinnacle Research Group LLC | Anniston, Alabama, United States | — |
| Univ of Alabama Birmingham | Birmingham, Alabama, United States | — |
| Chambliss Clinical Trials LLC | Montgomery, Alabama, United States | — |
| Providence Medical Foundation | Fullerton, California, United States | — |
| Torrance Clinical Research Institute, Inc. | Lomita, California, United States | — |
| Diablo Clinical Research, Inc. | Walnut Creek, California, United States | — |
| Univ of Colorado at Denver | Aurora, Colorado, United States | — |
| ERG Holding Company, LLC / Evolution Research Group, LLC | Delray Beach, Florida, United States | — |
| Northeast Research Institute | Fleming Island, Florida, United States | — |
| Miguel Rebollar PA | Hialeah, Florida, United States | — |
| Jacksonville Ctr Clin Res | Jacksonville, Florida, United States | — |
| South Broward Research LLC | Miramar, Florida, United States | — |
+ 30 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07720271